Literature DB >> 22547006

Optic glioma in children: a retrospective analysis of 101 cases.

Ali Varan1, Abduselam Batu, Ayşenur Cila, Figen Soylemezoğlu, Serdar Balcı, Nejat Akalan, Faruk Zorlu, Canan Akyüz, Tezer Kutluk, Münevver Büyükpamukçu.   

Abstract

AIM: To evaluate the clinical characteristics and long-term outcome of pediatric patients with optic glioma. PATIENTS AND METHODS: A total of 101 patients with optic glioma newly diagnosed between 1975 and 2008 were evaluated retrospectively. COPP (cyclophosphamide, vincristine, procarbazine, prednisolone) and cisplatin plus etoposide were the most commonly used chemotherapy regimens. Radiotherapy was administered in patients with progressive or unresponsive disease.
RESULTS: The median age at the time of diagnosis was 6 years, and the male/female ratio was 1.15. The most common referral complaint was strabismus. The most common site of optic glioma was the hypothalamic-chiasmatic region (31.7%). Fifty-three patients (52.5%) had neurofibromatosis type 1 (NF-1). Treatment consisted of surgery, radiotherapy, and chemotherapy. Forty-nine patients (48.5%) underwent surgery, which was predominantly subtotal resection, radiotherapy was administered to 39.4%, and 30 patients received chemotherapy. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 65.8% and 88.4%, respectively, and the 10-year PFS and OS were 54.2% and 83.4%, respectively, with an 8-year median follow-up. OS was significantly lower in patients with hypothalamo-chiasmatic involvement and significantly higher in patients with NF-1. The 5- and 10-year PFS rates were significantly higher in patients 10 years or older at diagnosis (P=0.0001) and in patients with intraorbital involvement (P=0.032). Eighteen patients (17.8%) died of disease.
CONCLUSIONS: Patients with NF-l and those older than 10 years have a better prognosis, whereas patients younger than 3 years and those with hypothalamic-chiasmatic optic glioma have a worse outcome. Further studies are needed to find appropriate treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22547006     DOI: 10.1097/COC.0b013e3182467efa

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  8 in total

1.  Neuro-oncology: paediatric brain tumours--when to operate?

Authors:  Kaisorn L Chaichana; Alfredo Quinones-Hinojosa
Journal:  Nat Rev Neurol       Date:  2013-05-28       Impact factor: 42.937

2.  Cavernous malformation of the optic pathway mimicking optic glioma: a case report.

Authors:  Yui Mano; Toshihiro Kumabe; Ryuta Saito; Mika Watanabe; Teiji Tominaga
Journal:  Childs Nerv Syst       Date:  2014-07-03       Impact factor: 1.475

3.  Melatonin attenuates cisplatin-induced HepG2 cell death via the regulation of mTOR and ERCC1 expressions.

Authors:  Kangsadarn Bennukul; Sucha Numkliang; Vijittra Leardkamolkarn
Journal:  World J Hepatol       Date:  2014-04-27

4.  Optic nerve astrocytoma in a dog.

Authors:  Orr Rozov; Pablo E Piñeyro; Kurt L Zimmerman; Ian P Herring; Rachel Matusow; John H Rossmeisl; Bernard S Jortner; Jennifer Dreyfus
Journal:  Clin Case Rep       Date:  2016-07-27

5.  Extracranial metastasis of anaplastic oligoastrocytoma.

Authors:  Zhuang Kang; Shoubo Yang; Hongmei Zhang; Quan Zhou; Jianxin Chen; Yan Li; Xun Kang; Shan Li; Wenbin Li
Journal:  Cancer Biol Med       Date:  2018-08       Impact factor: 4.248

Review 6.  Supratentorial Pediatric Midline Tumors and Tumor-like Lesions: Clinical Spectrum, Natural History and Treatment Options.

Authors:  Luca Paun; Alexandre Lavé; Gildas Patet; Andrea Bartoli
Journal:  Children (Basel)       Date:  2022-04-09

Review 7.  Current update on the visual outcome of optic pathway glioma associated with neurofibromatosis type-1.

Authors:  Janice Lasky Zeid
Journal:  Front Surg       Date:  2022-09-02

Review 8.  Management of Optic Pathway Glioma: A Systematic Review and Meta-Analysis.

Authors:  Omid Yousefi; Pouria Azami; Mohammadmahdi Sabahi; Rocco Dabecco; Badih Adada; Hamid Borghei-Razavi
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.